Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]
NYS Entity Status
NYS Filing Date
FEBRUARY 20, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY
2013 - IFM INVESTORS (US) ADVISOR, LLC
2013 - IFM (US) INVESTMENT ADVISOR, LLC
AROUND THE WEB
- IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
By Ben Fidler - Thursday Aug 3, 2017
- Investor blasts Potbelly Sandwich, pushes for sale
By Carleton English - Friday Jun 23, 2017
An activist investor wants Potbelly Sandwich Works to put itself on the block. Cleveland-based investment firm Ancora Advisors sent the fast food chain’s board a letter Thursday, blasting it for its poor performance since the sandwich maker went public in 2013. “Investors have experienced nothing but losses as owners of Potbelly,” Ancora Chief Executive Fred...
- Dan Loeb buys a chunk of Nestle, blasts ‘staid’ culture
By Carleton English - Monday Jun 26, 2017
Dan Loeb just placed his biggest bet ever on a chocolate company. The activist investor’s hedge fund Third Point LLC amassed a $3.5 billion stake in Nestle, the world’s largest packaged foods company, representing roughly 1.25 percent of the Swiss-based company’s shares. Loeb is hoping to reinvigorate the brand amid changing food tastes as well...
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.
- Martin Shkreli is found guilty of fraud
By Stephanie Clifford and Colin Moynihan - Friday Aug 4, 2017
NEW YORK — Martin Shkreli, accused of defrauding his hedge fund investors and a pharmaceutical company, was convicted on three of eight counts on Friday, after a five-week trial in U.S. District Court in Brooklyn, N.Y.Shkreli was accused of securities and wire fraud related to two hedge funds he ran, MSMB Capital and MSMB Healthcare.The prosecution brought forth an “avalanche” of evidence, as prosecutor Jacquelyn Kasulis put it in her rebuttal argument, that included a threatening letter he sent to the wife of a former employee, statements he sent to MSMB investors showing great returns at the same time he had no money in fund accounts, three versions of a backdated agreement to make it look as if MSMB Capital had invested in Retrophin when it had not, as well as claims about assets under management that were wildly out of line with his actual fund size.